Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 197

1.

PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.

Ren Z, Ahn JH, Liu H, Tsai YH, Bhanu NV, Koss B, Allison DF, Ma A, Storey AJ, Wang P, Mackintosh SG, Edmondson RD, Groen RWJ, Martens AC, Garcia BA, Tackett AJ, Jin J, Cai L, Zheng D, Wang GG.

Blood. 2019 Oct 3;134(14):1176-1189. doi: 10.1182/blood.2019000578. Epub 2019 Aug 5.

PMID:
31383640
2.

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.

Mileshkin L, Edmondson R, O'Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, Clamp A, Green J, Lord R, Amant F, Alexander L, Carty K, Paul J, Scurry J, Millan D, Nottley S, Friedlander M; PARAGON study group.

Gynecol Oncol. 2019 Jul;154(1):29-37. doi: 10.1016/j.ygyno.2019.05.007. Epub 2019 May 23.

PMID:
31130288
3.

Epithelial ovarian cancer risk: A review of the current genetic landscape.

Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG.

Clin Genet. 2019 May 16. doi: 10.1111/cge.13566. [Epub ahead of print] Review.

PMID:
31099061
4.

The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome.

Crosbie EJ, Ryan NAJ, Arends MJ, Bosse T, Burn J, Cornes JM, Crawford R, Eccles D, Frayling IM, Ghaem-Maghami S, Hampel H, Kauff ND, Kitchener HC, Kitson SJ, Manchanda R, McMahon RFT, Monahan KJ, Menon U, Møller P, Möslein G, Rosenthal A, Sasieni P, Seif MW, Singh N, Skarrott P, Snowsill TM, Steele R, Tischkowitz M; Manchester International Consensus Group, Evans DG.

Genet Med. 2019 Oct;21(10):2390-2400. doi: 10.1038/s41436-019-0489-y. Epub 2019 Mar 28.

5.

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA; BriTROC investigators.

Br J Cancer. 2019 Apr;120(8):868. doi: 10.1038/s41416-019-0433-6.

6.

Proteomic characterization of the arsenic response locus in S. cerevisiae.

West KL, Byrum SD, Mackintosh SG, Edmondson RD, Taverna SD, Tackett AJ.

Epigenetics. 2019 Feb;14(2):130-145. doi: 10.1080/15592294.2019.1580110. Epub 2019 Mar 1.

PMID:
30739529
7.

Metaproteomics reveals potential mechanisms by which dietary resistant starch supplementation attenuates chronic kidney disease progression in rats.

Zybailov BL, Glazko GV, Rahmatallah Y, Andreyev DS, McElroy T, Karaduta O, Byrum SD, Orr L, Tackett AJ, Mackintosh SG, Edmondson RD, Kieffer DA, Martin RJ, Adams SH, Vaziri ND, Arthur JM.

PLoS One. 2019 Jan 30;14(1):e0199274. doi: 10.1371/journal.pone.0199274. eCollection 2019.

8.

Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.

Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J, Mitchell CL, Schlecht H, Woodward ER, Lallo FI, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR.

J Med Genet. 2019 May;56(5):301-307. doi: 10.1136/jmedgenet-2018-105792. Epub 2019 Jan 25.

PMID:
30683677
9.

Impact of surgical site infection (SSI) following gynaecological cancer surgery in the UK: a trainee-led multicentre audit and service evaluation.

O'Donnell RL, Angelopoulos G, Beirne JP, Biliatis I, Bolton H, Bradbury M, Craig E, Gajjar K, Mackintosh ML, MacNab W, Madhuri TK, McComiskey M, Myriokefalitaki E, Newton CL, Ratnavelu N, Taylor SE, Thangavelu A, Rhodes SA, Crosbie EJ, Edmondson RJ, Wan YL.

BMJ Open. 2019 Jan 24;9(1):e024853. doi: 10.1136/bmjopen-2018-024853.

10.

Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.

Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ.

Cancer Res. 2019 Mar 15;79(6):1113-1123. doi: 10.1158/0008-5472.CAN-18-1722. Epub 2019 Jan 23.

PMID:
30674537
11.

Survival of women with early-stage cervical cancer in the UK treated with minimal access and open surgery.

Martin-Hirsch P, Wood N, Whitham NL, Macdonald R, Kirwan J, Anagnostopoulos A, Hutson R, Theophilou G, Otify M, Smith M, Myriokefalitaki E, Quinland W, Mahon-Daly F, Clayton RD, Nagar H, Harley I, Dobbs S, Ratnavelu N, Kucukmetin A, Fisher AD, Tailor A, Butler-Manuel S, Madhuri K, Edmondson RJ.

BJOG. 2019 Jul;126(8):956-959. doi: 10.1111/1471-0528.15617. Epub 2019 Mar 1. No abstract available.

PMID:
30658010
12.

Label-Free Proteomic Approach to Characterize Protease-Dependent and -Independent Effects of sarA Inactivation on the Staphylococcus aureus Exoproteome.

Byrum SD, Loughran AJ, Beenken KE, Orr LM, Storey AJ, Mackintosh SG, Edmondson RD, Tackett AJ, Smeltzer MS.

J Proteome Res. 2018 Oct 5;17(10):3384-3395. doi: 10.1021/acs.jproteome.8b00288. Epub 2018 Sep 27.

13.

Copy number signatures and mutational processes in ovarian carcinoma.

Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD.

Nat Genet. 2018 Sep;50(9):1262-1270. doi: 10.1038/s41588-018-0179-8. Epub 2018 Aug 13.

14.

Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.

Owens GL, Price MJ, Cheadle EJ, Hawkins RE, Gilham DE, Edmondson RJ.

Cancer Immunol Immunother. 2018 Oct;67(10):1519-1531. doi: 10.1007/s00262-018-2211-3. Epub 2018 Jul 23.

15.

Proteomic Analysis for Identification of Biomarkers that Predict Severe Acute Kidney Injury.

Arthur JM, Karakala N, Edmondson RD.

Nephron. 2018;140(2):129-133. doi: 10.1159/000491440. Epub 2018 Jul 10. Review.

16.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

PMID:
29955143
17.

DNA damage repair in ovarian cancer: unlocking the heterogeneity.

Gee ME, Faraahi Z, McCormick A, Edmondson RJ.

J Ovarian Res. 2018 Jun 20;11(1):50. doi: 10.1186/s13048-018-0424-x. Review.

18.

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC.

Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658. doi: 10.1007/s00280-018-3532-9. Epub 2018 Feb 20. Review.

19.

Population-based testing of non-mucinous epithelial ovarian cancer in Scotland.

Evans DG, Edmondson R, Crosbie EJ.

BJOG. 2018 Oct;125(11):1459. doi: 10.1111/1471-0528.15174. Epub 2018 May 10. No abstract available.

20.

Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.

Kitson S, Ryan N, MacKintosh ML, Edmondson R, Duffy JM, Crosbie EJ.

Cochrane Database Syst Rev. 2018 Feb 1;2:CD012513. doi: 10.1002/14651858.CD012513.pub2. Review.

Supplemental Content

Loading ...
Support Center